Literature DB >> 24668645

A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease.

Michael D Onken1, Ashley E Winkler1, Krishna-Latha Kanchi1, Varun Chalivendra1, Jonathan H Law1, Charles G Rickert1, Dorina Kallogjeri1, Nancy P Judd1, Gavin P Dunn1, Jay F Piccirillo1, James S Lewis2, Elaine R Mardis2, Ravindra Uppaluri3.   

Abstract

PURPOSE: Improved understanding of the molecular basis underlying oral squamous cell carcinoma (OSCC) aggressive growth has significant clinical implications. Herein, cross-species genomic comparison of carcinogen-induced murine and human OSCCs with indolent or metastatic growth yielded results with surprising translational relevance. EXPERIMENTAL
DESIGN: Murine OSCC cell lines were subjected to next-generation sequencing (NGS) to define their mutational landscape, to define novel candidate cancer genes, and to assess for parallels with known drivers in human OSCC. Expression arrays identified a mouse metastasis signature, and we assessed its representation in four independent human datasets comprising 324 patients using weighted voting and gene set enrichment analysis. Kaplan-Meier analysis and multivariate Cox proportional hazards modeling were used to stratify outcomes. A quantitative real-time PCR assay based on the mouse signature coupled to a machine-learning algorithm was developed and used to stratify an independent set of 31 patients with respect to metastatic lymphadenopathy.
RESULTS: NGS revealed conservation of human driver pathway mutations in mouse OSCC, including in Trp53, mitogen-activated protein kinase, phosphoinositide 3-kinase, NOTCH, JAK/STAT, and Fat1-4. Moreover, comparative analysis between The Cancer Genome Atlas and mouse samples defined AKAP9, MED12L, and MYH6 as novel putative cancer genes. Expression analysis identified a transcriptional signature predicting aggressiveness and clinical outcomes, which were validated in four independent human OSCC datasets. Finally, we harnessed the translational potential of this signature by creating a clinically feasible assay that stratified patients with OSCC with a 93.5% accuracy.
CONCLUSIONS: These data demonstrate surprising cross-species genomic conservation that has translational relevance for human oral squamous cell cancer. Clin Cancer Res; 20(11); 2873-84. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24668645      PMCID: PMC4096804          DOI: 10.1158/1078-0432.CCR-14-0205

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Support vector machine classification on the web.

Authors:  Paul Pavlidis; Ilan Wapinski; William Stafford Noble
Journal:  Bioinformatics       Date:  2004-01-22       Impact factor: 6.937

2.  Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue.

Authors:  J N Myers; J S Greenberg; V Mo; D Roberts
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

Review 3.  Evidence-based practice: management of the clinical node-negative neck in early-stage oral cavity squamous cell carcinoma.

Authors:  Marcus M Monroe; Neil D Gross
Journal:  Otolaryngol Clin North Am       Date:  2012-10       Impact factor: 3.346

4.  ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Authors:  Nancy P Judd; Ashley E Winkler; Oihana Murillo-Sauca; Joshua J Brotman; Jonathan H Law; James S Lewis; Gavin P Dunn; Jack D Bui; John B Sunwoo; Ravindra Uppaluri
Journal:  Cancer Res       Date:  2011-11-15       Impact factor: 12.701

5.  The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.

Authors:  Christian Cordes; Robert Häsler; Christian Werner; Tibor Görögh; Christoph Röcken; Lena Hebebrand; W Martin Kast; Markus Hoffmann; Stefan Schreiber; Petra Ambrosch
Journal:  Int J Oncol       Date:  2011-04-14       Impact factor: 5.650

6.  Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.

Authors:  Hideo Watanabe; Joshua M Francis; Michele S Woo; Banafsheh Etemad; Wenchu Lin; Daniel F Fries; Shouyong Peng; Eric L Snyder; Purushothama Rao Tata; Francesca Izzo; Anna C Schinzel; Jeonghee Cho; Peter S Hammerman; Roel G Verhaak; William C Hahn; Jayaraj Rajagopal; Tyler Jacks; Matthew Meyerson
Journal:  Genes Dev       Date:  2013-01-15       Impact factor: 11.361

7.  A 13-gene signature prognostic of HPV-negative OSCC: discovery and external validation.

Authors:  Pawadee Lohavanichbutr; Eduardo Méndez; F Christopher Holsinger; Tessa C Rue; Yuzheng Zhang; John Houck; Melissa P Upton; Neal Futran; Stephen M Schwartz; Pei Wang; Chu Chen
Journal:  Clin Cancer Res       Date:  2013-01-14       Impact factor: 12.531

Review 8.  NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.

Authors:  Tomoya Yamaguchi; Yasuyuki Hosono; Kiyoshi Yanagisawa; Takashi Takahashi
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

9.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

10.  Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.

Authors: 
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  54 in total

1.  Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Authors:  Paul E Clavijo; Jay Friedman; Yvette Robbins; Ellen C Moore; Ernest Smith; Maurice Zauderer; Elizabeth E Evans; Clint T Allen
Journal:  Cancer Immunol Res       Date:  2018-12-04       Impact factor: 11.151

2.  Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Authors:  Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

Review 3.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

4.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Authors:  Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen
Journal:  JCI Insight       Date:  2019-04-04

Review 5.  Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.

Authors:  Jose Augusto Monteiro de Oliveira Novaes; William N William
Journal:  Future Oncol       Date:  2016-06-22       Impact factor: 3.404

6.  Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.

Authors:  Ellen Moore; Paul E Clavijo; Ruth Davis; Harrison Cash; Carter Van Waes; Young Kim; Clint Allen
Journal:  Cancer Immunol Res       Date:  2016-11-07       Impact factor: 11.151

7.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

8.  Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.

Authors:  Priya Patel; Lily Sun; Yvette Robbins; Paul E Clavijo; Jay Friedman; Christopher Silvin; Carter Van Waes; John Cook; James Mitchell; Clint Allen
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

9.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

10.  Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies.

Authors:  Sujay Shah; Andria Caruso; Harrison Cash; Carter Van Waes; Clint T Allen
Journal:  Head Neck       Date:  2016-04-09       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.